Supreme Court Denounces Cancer Drug Pricing, Questions Rs 27,000 MRP

The Supreme Court of India has raised sharp concerns over the pricing of cancer drugs, describing the situation as "carnage, plain and simple." The court's intervention comes after examining cases where drugs manufactured at Rs 3,000 are retailed at Rs 27,000, creating an enormous price-to-retail markup that strains government coffers.

During hearings, the bench questioned established practices in hospital pharmacies and the role of intermediaries in inflating drug prices. The court expressed particular concern about the impact on taxpayers, whose contributions to government health insurance schemes absorb these inflated costs. The markup structure effectively transfers financial burden from manufacturers to patients and public healthcare systems.

The intervention highlights ongoing tensions between pharmaceutical pricing regulations and retail markups in India's healthcare sector. While the government regulates manufacturing prices through price control mechanisms, the addition of multiple layers of distribution costs and hospital margins significantly increases final consumer prices.

The court's scrutiny suggests potential judicial intervention in pharmaceutical pricing practices, particularly for essential cancer medications covered under government health schemes. The proceedings could prompt review of current pharmacy markup policies and transparency requirements in drug pricing chains across India's healthcare system.